MedTrace Logo

Lung Microbiota and VAP Development (PULMIVAP)

NCT04849039 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2021-04-19

No results posted yet for this study

Summary

Ventilator-associated pneumonia (VAP) refers to a lower respiratory tract nosocomial infection acquired \>48h after being intubated in Intensive Care Units. Pathogenesis of VAP is mechanical and associated with microaspiration and leakage of oropharyngeal secretions around the endotracheal tube. A novel approach to VAP will attempt to explore how the abrupt ecological order of acute infection (high bacterial biomass, low community diversity) emerges from the dynamic homeostasis of a pre-existing ecosystem in which lung microbiota and local immunity interaction play their essential role.

Therefore, the investigators aim to explore if oral and lung microbiota modifications with local immunity changes, contribute in the pathogenesis of VAP in patients intubated for non-pulmonary reasons. Early changes in the host microbiota with the innate immunity system impairs tissue homeostasis and may represent a new distinct condition and a potential tool for early diagnosis and prevention of VAP.

Conditions

  • Mechanical Ventilation

Sponsors & Collaborators

  • San Gerardo Hospital

    collaborator OTHER

  • University of Parma

    collaborator OTHER

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-10
Primary Completion
2022-11-01
Completion
2023-01-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04849039 on ClinicalTrials.gov